Skip to main content

Research Repository

Advanced Search

The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome

Sathyapalan, Thozhukat; Hobkirk, James P.; Javed, Zeeshan; Carroll, Sean; Coady, Anne Marie; Pemberton, Philip; Smith, Alexander; Cianflone, Katherine; Atkin, Stephen L.

Authors

Profile Image

Dr James Hobkirk J.Hobkirk@hull.ac.uk
Lecturer in Physiology & Pathophysiology & Honorary Medical Scientist

Zeeshan Javed

Anne Marie Coady

Philip Pemberton

Alexander Smith

Katherine Cianflone

Stephen L. Atkin



Abstract

Copyright © 2019 Sathyapalan, Hobkirk, Javed, Carroll, Coady, Pemberton, Smith, Cianflone and Atkin. Background: Atorvastatin has been shown to improve cardiovascular risk (CVR) indices in women with polycystic ovary syndrome (PCOS). Low-grade chronic inflammation of adipose tissue may link PCOS and adverse CVR. In pro-inflammatory states such as PCOS, spontaneous activation of the alternative pathway of complement results in increased generation of acylation stimulating protein (ASP) from adipocytes irrespective of body mass index. Methods: The objective of this study was to determine the effect of atorvastatin on markers of adipose tissue dysfunction and inflammation; acylation-stimulating-protein (ASP), interleukin-6 (IL-6), and monocyte-chemoattractant-protein-1 (MCP-1) in PCOS. This was a randomized, double-blind, placebo-controlled study where 40 medication-naive women with PCOS and biochemical hyperandrogenaemia were randomized to either atorvastatin 20 mg daily or placebo for 12 weeks. Following the 12 week randomization; both group of women with PCOS were subsequently started on metformin 1,500 mg daily for further 12 weeks to assess whether pre-treatment with atorvastatin potentiates the effects of metformin on markers of adipose tissue function We conducted a post-hoc review to detect plasma ASP and the pro-inflammatory cytokines IL6 and MCP-1 before and after 12 and 24 weeks of treatment. Results: There was significant reduction in ASP (156.7 ± 16.2 vs. 124.4 ± 14.8 ng/ml p

Citation

Sathyapalan, T., Hobkirk, J. P., Javed, Z., Carroll, S., Coady, A. M., Pemberton, P., …Atkin, S. L. (2019). The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in endocrinology, 10(JUN), Article 394. https://doi.org/10.3389/fendo.2019.00394

Journal Article Type Article
Acceptance Date Jun 4, 2019
Online Publication Date Jun 25, 2019
Publication Date Jun 25, 2019
Deposit Date Jun 25, 2019
Publicly Available Date Mar 28, 2024
Journal Frontiers in Endocrinology
Print ISSN 1664-2392
Electronic ISSN 1664-2392
Publisher Frontiers Media
Peer Reviewed Peer Reviewed
Volume 10
Issue JUN
Article Number 394
DOI https://doi.org/10.3389/fendo.2019.00394
Keywords Atorvastatin; Acylation-stimulating-protein; Interleukin-6; Monocyte-chemoattractant-protein-1; Adipose tissue; PCOS
Public URL https://hull-repository.worktribe.com/output/2038521
Publisher URL https://www.frontiersin.org/articles/10.3389/fendo.2019.00394/full

Files


Published article (514 Kb)
PDF

Copyright Statement
Copyright © 2019 Sathyapalan, Hobkirk, Javed, Carroll, Coady, Pemberton, Smith, Cianflone and Atkin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.





You might also like



Downloadable Citations